Clinical trials: Cancer in the Lung
Non-small-Cell Lung Carcinoma, Surgery
N2 Lung Cancer Project: Neoadjuvant Treatment Followed Surgery Versus Chemoradiation
The objective of this multicenter retrospective study is to compare overall survival in patients with stage IIIA-N2 NSCLC treated with neoadjuvant treatment and surgery versus definitive chemoradiation.
- Conditions
- Non-small-Cell Lung Carcinoma, Surgery, Stage IIIA-N2, Chemoradiation
- Trial name
- NCT02966769
- Testing
- Overall survival
- Where
- Spain
- Volunteers
- 294 people
- Sponsor
- Grupo de Investigación Clínica en Oncología Radioterapia
Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients
To evaluate the efficacy and safety of glumetinib combined with osimertinib as the first-line treatment for locally advanced or metastatic NSCLC.
- Trial name
- NCT06908772
- Testing
- Glumetinib Tablets, Osimertinib Mesylate Tablets
- Volunteers
- 390 people
- Sponsor
- Shanghai JMT-Bio Inc.
Non Small Cell Lung Cancer
XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
The trial is divided into two parts, one is dose escalation phase, the second one is dose expansion phase. For dose escalation phase, the main purpose is to evaluate safety and tolerability of XZP-5809-TT1 tablets after treatment…
- Trial name
- NCT04622072
- Testing
- XZP-5809-TT1 Tablet
- Where
- 5 sites in China
- Volunteers
- 21 people
- Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
Cancer, Covid19
CCP Cancer UK Companion Study
Currently, there is extremely limited information regarding the risks posed by SARS-CoV-2 to patients with cancer. This study aims to understand the presentation, management and outcomes of patients with cancer.
- Trial name
- NCT04603105
- Where
- United Kingdom
- Volunteers
- 9,000 people
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
Survival Prolongation by Rationale Innovative Genomics
Patients with advanced/metastatic non-small cell lung cancer (NSCLC) with no documented targetable alterations (Epidermal Growth Factor Receptor (EGFR) mutation, Anaplastic Lymphoma Kinase (ALK) translocation, ROS1 mutation if…
- Trial name
- SPRING (NCT03386929)
- Testing
- Avelumab, Axitinib, Palbociclib
- Where
- 5 sites in United States, Israel and 2 more
- Volunteers
- 15 people
- Sponsor
- Worldwide Innovative Network Association
Non-Small-Cell Lung Cancer
Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC
This is a Prospective, open label, single arm study to evaluate the efficacy and safety of Vebreltinib combined with Osimertinib in the treatment of locally advanced or metastatic non-small cell lung cancer with EGFR 21 L858R…
- Trial name
- NCT06827145
- Testing
- Vebreltinib, Osimertinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- National Cancer Center, China
Sarcoma, Cervical Cancer
A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
The present trial is an open, single-arm phase I clinical study aimed at assessing the safety, tolerability, viral distribution and shedding patterns, pharmacodynamics, immunogenicity, and antitumor efficacy of GC001 oncolytic…
- Conditions
- Sarcoma, Cervical Cancer, Colon Cancer, Lung Cancer
- Trial name
- NCT06508307
- Testing
- A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patients With Advanced Solid Tumors
- Where
- China
- Volunteers
- 21 people
- Sponsor
- GONGCHU Biotechnology Co., Ltd
Lung Neoplasms, Respiratory Tract Neoplasms
Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC
This Expanded Access Program will provide access of taletrectinib therapy to patients with locally advanced or metastatic ROS1-positive NSCLC who are not an appropriate candidate for an approved therapy, for any ongoing…
- Conditions
- Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site
- Trial name
- Tale EAP (NCT06841874)
- Testing
- Taletrectinib
- Sponsor
- Nuvation Bio Inc.
Cancer, Deep-vein Thrombosis of the Lower and Upper Extremities
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
The primary objective of this study is to evaluate the practice patterns of rivaroxaban usage invenous-thromboembolism (VTE) and non-valvular atrial fibrillation (NVAF) in cancer patients.
- Conditions
- Cancer, Deep-vein Thrombosis of the Lower and Upper Extremities, Pulmonary Embolism, Non-valvular Atrial Fibrillation
- Trial name
- NCT02502396
- Testing
- Retrospective Chart Review
- Where
- United States
- Volunteers
- 265 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
- Trial name
- NCT04449874
- Testing
- GDC-6036, Atezolizumab, Cetuximab
- Where
- 63 sites in United States, Australia and 15 more
- Volunteers
- 498 people
- Sponsor
- Genentech, Inc.
NSCLC Stage IV, EGFR T790M-negative
Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
This study is designed to evaluate the efficacy and safety of the combination of Anlotinb and JS001 in EGFR-TKI resistant T790M-negative NSCLC patients.
- Conditions
- NSCLC Stage IV, EGFR T790M-negative, Anlotinib, JS001
- Trial name
- NCT04116918
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Baodong Qin
Ovarian Cancer, Non Small Cell Lung Cancer
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
The purpose of the study is to estimate the rate of response for patients with ovarian, non-small cell lung, prostate, colorectal, gastroesophageal, and head and neck cancers who are administered LY2523355.
- Conditions
- Ovarian Cancer, Non Small Cell Lung Cancer, Prostate Cancer, Colorectal Cancer
- Trial name
- NCT01059643
- Testing
- LY2523355, pegfilgrastim
- Where
- 18 sites in United States
- Volunteers
- 103 people
- Sponsor
- Eli Lilly and Company
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung, ErbB Receptors
Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)
There is a medical need for improving treatment of poor performance status patients with EGFR driver mutations and documenting safety and tolerability of existing agents.
- Trial name
- NCT02695290
- Testing
- Afatinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Boehringer Ingelheim
NSCLC Stage IV, Brain Metastases
Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC
This is a phase II, Open-Label, Multicenter, Prospective Clinical Study to Investigate the Efficacy and Safety of Tislelizumab Combined with Pemetrexed/ Carboplatin in Patients with Brain Metastases of Non-squamous Non-small Cell…
- Conditions
- NSCLC Stage IV, Brain Metastases, PD-1 Antibody
- Trial name
- NCT04507217
- Testing
- Tislelizumab, Carboplatin, Pemetrexed
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
To assess efficacy and safety of oral TQ-B3101 administered to patients with Advanced Non-Small Cell Lung Cancer (NSCLC) that confirmed ROS1 positive gene mutation.
- Trial name
- NCT03972189
- Testing
- TQ-B3101
- Where
- 22 sites in China
- Volunteers
- 111 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Carcinoma, Non-Small-Cell Lung
VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)
This observational study will investigate the efficacy and tolerability of Vargatef (Nintedanib) plus docetaxel in daily routine second-line treatment in patients with locally advanced, metastatic or locally recurrent NSCLC.
- Trial name
- NCT02392455
- Testing
- treatment
- Where
- Germany
- Volunteers
- 817 people
- Sponsor
- Boehringer Ingelheim
Non-small Cell Lung Cancer, Pancreatic Cancer
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.
- Conditions
- Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Loss of Appetite
- Trial name
- PROACC-1 (NCT05546476)
- Testing
- ponsegromab
- Where
- 78 sites in United States, Australia and 9 more
- Volunteers
- 187 people
- Sponsor
- Pfizer
Chronic Disease, Diabetes
Pragmatic Randomized Control Trial of Telehealth vs Standard Care in Follow-up of Patients With Chronic Conditions
The Norwegian health authorities has initiated a three-year trial of telehealth solutions as part of the treatment of patients with chronic illness in the period 2018-2021.
- Conditions
- Chronic Disease, Diabetes, Vascular Diseases, Chronic Lung Disease
- Trial name
- MAO (NCT04142710)
- Testing
- Telemedicine: tablet and possibly tools to perform measurements
- Where
- 9 sites in Norway
- Volunteers
- 732 people
- Sponsor
- University of Oslo
Lung Cancer, Circulating Tumor DNA
NSCLC Liquid Biopsies and Exhaled VOC
The objective of the study is to determine the feasibility of recruiting participants and using sputum, Bronchoalveolar lavage (BAL) and exhaled Volatile Organic Compounds (VOC) in addition to blood, as biological samples for…
- Trial name
- NCT06707519
- Where
- Canada
- Volunteers
- 210 people
- Sponsor
- St. Joseph's Healthcare Hamilton
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.